Sam Brusco, Associate Editor06.11.24
Delphinus Medical Technologies has welcomed Michael Emery as its new chief financial officer (CFO).
Emery touts over 30 years of experience in financial executive leadership in the pharma and medical device industries. He was previously CFO and chief operating officer (COO) at Tyber Medical, an orthopedic company focused on the spine and extremity/trauma markets.
Before Tyber, Emery headed financial executive teams at Plasma Surgical and Abbott Pharmaceuticals. He spent over a decade in the position at Abbott, beginning at Solvay Pharmaceuticals and aligning it for purchase and integrating business operations into Abbott.
Most recently, Emery consulted for multiple companies in healthcare and medical devices.
“It is an honor to join a company that is experiencing immense growth as it enters into commercial stage,” said Emery. “The SoftVue system addresses a large gap in the U.S. healthcare system for women with dense breast tissue, and I look forward to supporting Delphinus’s expansion in the healthcare market and enabling the company to achieve all of its current and future business goals.”
“Michael’s strong resume of strategic planning, financial management and building high-performance teams, makes him the ideal leader to help us execute our financial plan here at Delphinus,” said Delphinus CEO Scott White. “We are in an exciting time for our organization, where the potential for growth and long-term goal achievement is paramount and requires a financial leader who can position us for success.”
SoftVue screens women with dense breasts, in addition to mammography. It delivers no radiation, needs no compression, and images the whole breast in one scan.
The company said when paired with standard screening, SoftVue was able to spot up to 20% more cancers. It also reduced false positives and decreased unnecessary false positives and biopsies.
Emery touts over 30 years of experience in financial executive leadership in the pharma and medical device industries. He was previously CFO and chief operating officer (COO) at Tyber Medical, an orthopedic company focused on the spine and extremity/trauma markets.
Before Tyber, Emery headed financial executive teams at Plasma Surgical and Abbott Pharmaceuticals. He spent over a decade in the position at Abbott, beginning at Solvay Pharmaceuticals and aligning it for purchase and integrating business operations into Abbott.
Most recently, Emery consulted for multiple companies in healthcare and medical devices.
“It is an honor to join a company that is experiencing immense growth as it enters into commercial stage,” said Emery. “The SoftVue system addresses a large gap in the U.S. healthcare system for women with dense breast tissue, and I look forward to supporting Delphinus’s expansion in the healthcare market and enabling the company to achieve all of its current and future business goals.”
“Michael’s strong resume of strategic planning, financial management and building high-performance teams, makes him the ideal leader to help us execute our financial plan here at Delphinus,” said Delphinus CEO Scott White. “We are in an exciting time for our organization, where the potential for growth and long-term goal achievement is paramount and requires a financial leader who can position us for success.”
More about Delphinus Medical Technologies
The Novi, Mich.-based company developed SoftVue, an FDA-approved whole breast ultrasound tomography system.SoftVue screens women with dense breasts, in addition to mammography. It delivers no radiation, needs no compression, and images the whole breast in one scan.
The company said when paired with standard screening, SoftVue was able to spot up to 20% more cancers. It also reduced false positives and decreased unnecessary false positives and biopsies.